Definium Therapeutics, Inc. · NASDAQ:DFTX
Definium Therapeutics — Mind Medicine (MindMed) — Q3 2023 Earnings Presentation
20 slides from Definium Therapeutics's earnings presentation, Nov 2, 2023
Slide 1: Third Quarter 2023 Financial Results and Business Update
Logo Third Quarter 2023 Financial Results and Business Update November 2, 2023
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) has been preparedby Mind Medicine(MindMed) Inc. (“MindMed” or the “Company”) solely for informational purposes. None of MindMed, its affiliates or any of their respective employees, directors, officers, contractors, advisors, members, successors, rep
Slide 3: Third Quarter Financial Results and Business Update Call Participants
MindMed Third Quarter Financial Results and Business Update Call Participants Robert Barrow Chief Executive Officer and Board Director Schond Greenway, MBA Chief Financial Officer Daniel Karlin, MD, MA Chief Medical Officer Francois Lilienthal, MD, MBA Chief Commercial Officer Q3 2023 Earnings Prese
Slide 4: We Aim To Be A Global Leader In Brain Health
We Aim To Be A Global Leader In Brain Health A Diversified pipeline of clinical programs targeting significant unmet medical needs Advanced clinical development of product candidates MM-120: Phase 2b – dose-optimization (GAD) MM-120: Phase 2a – proof-of-concept (ADHD) MM-402: IND-enabling MM-402: Ph
Slide 5: Urgent Need for Better Treatments for Brain Health Disorders
Urgent Need for Better Treatments for Brain Health Disorders 10% 4.4% $461B 1-year prevalence of anxiety disorders in the US 1 estimated prevalence of ADHD among US adults2 economic cost of ASD in the US predicted by 2025 3 GAD ADHD ASD 1 in 4 U.S. Adults has a Diagnosable Mental Health Disorder 1 1
Slide 6: Diversified Pipeline Of Product Candidates Targeting Significant Unmet Needs
Diversified Pipeline Of Product Candidates Targeting Significant Unmet Needs PSYCHIATRY MM-120 (LSD D-tartrate) Generalized Anxiety Disorder ADHD MM-402 (R(-)-MDMA) Autism Spectrum Disorder OTHER PROGRAMS MM-110 (zolunicant HCl)* Opioid Withdrawal DISCOVERY & EARLY DEVELOPMENT Novel tryptamines undi
Slide 7: Addressing a Large Unmet Need for Better Anxiety Treatments
MM-120 | Addressing a Large Unmet Need for Better Anxiety Treatments Opportunity in Generalized Anxiety Disorder (GAD)GAD is the 2nd most common mental disorder among adults 18 to 65 years old 1 , yet choices are limited beyond SSRI/SNRIs Symptoms are debilitating and side effects / lack of efficacy
Slide 8: Proof-of-Concept of Outpatient Delivery in ADHD
MM-120 | Proof-of-Concept of Outpatient Delivery in ADHD We are optimizing MM-120 across indications through the study of various doses and regimens, such as in the current Phase 2a trial in ADHD. Approach could be applicable to additional serotonin-mediated conditions with the potential for additio
Slide 9: MM-402 | Addressing the Urgent Need For Novel ASD Therapies
MM-402 | Addressing the Urgent Need For Novel ASD Therapies MM-402 | Addressing the Urgent Need For Novel ASD Therapies Translational pre-clinical data suggest that MM-402’s pharmacological profile may align with patient-desired treatment benefits in ASD MM-402 is a pharmaceutically preferential ena
Slide 10: LSD D-tartrate for Generalized Anxiety Disorder (GAD)
MM-120 LSD D-tartrate for Generalized Anxiety Disorder (GAD) Q3 2023 Earnings Presentation | November 2023 mindmed 10 logo
Slide 11: Lysergide Has Proven Potential Across Multiple Therapeutic Areas
Lysergide Has Proven Potential Across Multiple Therapeutic Areas Gasser P, Holstein D, Michel Y et al. 2014; J. Nerv. Ment. Dis.; 202(7). Fuentes JJ, Fonseca F, Elices M et al. 2020; Front Psychiatry; 10:943.1 2 Q3 2023 Earnings Presentation | November 2023 psychiatry broad applicability preliminary
Slide 12: Phase 2b Generalized Anxiety Disorder (GAD)
MM-120 | Phase 2b Generalized Anxiety Disorder (GAD) psychiatry mm 120 (lds d-tartarte indication gad phase2b 198 participants total actual week 5 to 1 1 2 4 8 12 prep dose follow up mm120 200 ug mm 120 100 ug mm 120 50 ug placebo primary endpoint ham a randomize study mmed008 mm 120 for gad a phase
Slide 13: Trial Design Milestones for Psychedelic Drug Class
MM-120 | Trial Design Milestones for Psychedelic Drug Class FDA guidance and Phase 2b dose-finding study align with MindMed’s framework for designing well-controlled, scientifically rigorous trials to assess safety and efficacy in the psychedelic drug class Phase 2b design aligns well with FDA guida
Slide 14: Phase 2b GAD - Primary Analysis Multiple Comparison Procedure Modelling
MM-120 | Phase 2b Generalized Anxiety Disorder (GAD) - Primary Analysis Multiple Comparison Procedure Modelling (MCP-Mod) Statistical methodology for dose-response developed by Novartis in 2004 1 Involves establishing a dose-response signal using multiple comparison procedures and then estimating th
Slide 15: Illustrative Analysis of Pharmacologic Treatments for GAD
MM-120 | Illustrative Analysis of Pharmacologic Treatments for GAD1 Reported Mean Effect Size by Existing Therapeutic Drug Class1,2 Buspirone SSRIs Benzodiazapines 0.17 0.36* 0.38* 0 0.1 0.2 0.3 0.4 Effect size (ES) presents the adjusted to the mean difference in treatment response between placebo a
Slide 16: Potential to Leverage Existing Monitored Delivery Infrastructure
Potential to Leverage Existing Monitored Delivery Infrastructure Spravato® (esketamine) for the treatment of Major Depressive Disorder (MDD) Monitored Delivery Paradigm Established for Spravato 8 intranasal 2-hr treatments over a 4-week period (16 hours)1 with 4 additional 2-hr treatments over 4 wee
Slide 17: Financial Results
Financial Results MindMed Q3 2023 Earnings Presentation | November 2023 17 logo
Slide 18: Third Quarter 2023 Financial Results
Third Quarter 2023 Financial Results $ in Millions Q3 2023 Q3 2022 R&D Spending $13.2 $7.8 G&A Spending $8.4 $9.2 Operating Expenses $21.6 $17.0 Net cash used in operating activities $43.8 (9-month period ending Sept. 30, 2023) $37.3 (9-month period ending Sept. 30, 2022) Cash and cash equivalents $
Slide 19: Anticipated Near-Term Milestones
Anticipated Near-Term Milestones Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 MM-120 GAD Phase 2b 4-wk Topline MM-120 GAD Phase 2b 12-wk Topline MM-120 GAD Full data presentation at scientific meeting MM-120 ADHD Phase 2a Topline MM-402 Phase 1 initiation MM-402/R-MDMA Phase 1 IIT (UHB-sponsored) Topline
Slide 20: Q&A
MindMed Q&A MindMed Q3 2023 Earnings Presentation | November 2023 20 logo
Mind Medicine (MindMed) — Q3 2023 Earnings Presentation on 6ix